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INTRODUCTION 
 Diabetes Mellitus is a heterogenous group of metabolic disorders 
characterized by hyperglycemia resulting from defects in insulin 
secretion, insulin action or both1. Type 2 Diabetes is one of the major 
health problems all over the world.1 WHO recently reported that total 
diabetics in India in 2000 was 31.7 million and this number likely to 
increase to 79.4 million by 20302. 
 Autonomic dysfunction is common in diabetics but symptomatic 
autonomic neuropathy is not that common. Presence of Cardiac 
Autonomic Neuropathy(CAN) is responsible for  silent myocardial 
infarction and sudden death in diabetics. Hence recognizing cardiac 
dysautonomia early, which is asymptomatic will helpful to delay or arrest 
its progression. 
 Diabetic neuropathy is one of the common complications of 
diabetes and specifically autonomic neuropathy can affect several 
systems2. Diabetic autonomic neuropathy (DAN) is a serious and 
common complication of diabetes. DAN frequently coexists with other 
peripheral neuropathies and other diabetic complications, but DAN may 
be isolated, frequently preceding the detection of other complications. 
Despite its relationship to an increased  risk of cardiovascular mortality 
and its association with multiple symptoms and impairments, the 
significance of DAN has not been fully appreciated3. The autonomic 
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function tests are now widely used for the assessment of autonomic 
function. These tests are non-invasive and do not require sophisticated 
equipment. All that required is an electrocardiogram machine, Heart rate 
monitor and sphygmomanometer. This highlights the importance of 
simple non-invasive tools like ECG and sphygmomanometer in 
diagnosing asymptomatic cardiac autonomic neuropathy. 
 Type 2 diabetic patients with abnormal CVR tests may have 
increased mortality, and those combined with postural hypotension have 
higher mortality than those without 4. 
 In 1980, for the first time, an association of prolonged QTc interval 
with cardiac autonomic neuropathy was given, thereby opening the 
possibility of a rapid objective method for detecting cardiac autonomic 
neuropathy. Further studies demonstrated an association of prolonged 
QTc interval with cardiac dysautonomia in diabetes mellitus5. 
 This study is performed to estimate the Prevalence of 
Cardiovascular Autonomic Neuropathy with relation to duration of 
diabetes in our GGH and to check the utility of corrected QT interval in 
diagnosing it. 
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AIMS AND OBJECTIVES 
1. To evaluate the prevalence of Cardiovascular Autonomic 
Neuropathy in Type 2 Diabetes patients in our hospital. 
2. To correlate the prevalence of Cardiovascular Autonomic 
Neuropathy with duration of diabetes. 
3. To investigate the relationship between Cardiac Autonomic                  
Neuropathy and QTc interval prolongation. 
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REVIEW OF LITERATURE 
 The Diabetic pandemic is rapidly spreading and mostly affects 
developing countries like India. Indeed, India presently has the largest 
number of diabetic patients in the world and has been infamously dubbed 
as the ‘Diabetic capital of the world’. Although by definition, diabetes is 
characterized by elevated glucose concentrations, the impact of diabetes 
on both the health of individuals and on the health care systems, resides 
almost entirely in the long term complications of diabetes affecting 
almost every system in the body including eyes, kidneys, heart, feet and 
nerves.2    
 Neuropathy occurs more or less with the same frequency in both 
type 1 and type 2 diabetes, suggesting a common etiological mechanism 
based on chronic hyperglycemia .2 
 One of the most overlooked of all serious complications of diabetes 
is cardiovascular autonomic neuropathy (CAN), which encompasses 
damage to the autonomic nerve fibers that innervate the heart and blood 
vessels, resulting in abnormalities in heart rate control and vascular 
dynamics. The clinical manifestations are resting tachycardia, orthostasis, 
exercise intolerance, intra-operative cardiovascular liability, silent 
myocardial infarction [MI], and increased risk of mortality in the 
presence of CAN. It also demonstrates that autonomic dysfunction can 
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affect daily activities of individuals with diabetes and may invoke 
potentially life-threatening outcomes.4,5n  
Autonomic nervous system 
 The autonomic nervous system conveys sensory impulses from the 
blood vessels, the heart and all of the organs in the chest, abdomen and 
pelvis through nerves to other parts of the brain (mainly the medulla, 
pons and hypothalamus). These impulses often do not reach our 
consciousness, but elicit largely automatic or reflex responses through the 
efferent autonomic nerves, thereby eliciting appropriate reactions of the 
heart, the vascular system and all the organs of the body to variations in 
environmental temperature, posture, food intake, stressful experiences 
and other changes to which all individuals are exposed.   There are two 
major components of the autonomic nervous system, the sympathetic and 
the parasympathetic systems. The afferent nerves sub-serving both 
systems convey impulses from sensory organs, muscles, the circulatory 
system and all the organs of the body to the controlling centers in the 
medulla, pons and hypothalamus. 
 The   impulses of  the  parasympathetic  system  reach   the organs    
of  the body  through the cranial nerves 3, 7, 9, & 10, and  some  sacral  
nerves - to the eyes, the  gastrointestinal  system,  and other  organs.  The   
sympathetic   nerves   reach  their   end-organs through  more devious 
pathways down the spinal cord to clusters of sympathetic  nerve bodies 
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(ganglia) along the side of  spine where  the messages  are relayed to 
other nerve bodies (or neurons) that travel to a   large  extent  with  the  
blood vessels to all parts of the body. Through  these  nervous  pathways,  
the  autonomic nerves   convey stimuli  resulting in largely unconscious 
reflex, bodily adjustments such  as  in the  size  of  the  pupil,  the  
digestive  functions  of  the stomach  and  intestines,  the  rate  and  depth 
of respiration and dilatation  or  constriction  of  the  blood vessels.  
 The function of Autonomic nervous system in its regulation of the 
internal organ is highly independent. When the autonomic nervous are 
interrupted, these organ continue to function, but they are no longer as 
effective in maintaining homeostasis and adapting to the demands of 
changing internal condition and external stress. 
 Autonomic dysfunction 
 Impairment of Autonomic function may occur as part of the more 
common acute or chronic peripheral neuropathies (e.g: Diabetic, 
alcoholic-nutritional, Amyloidosis, Gullain-Barre syndrome, infections, 
heavy metal toxic and porphyrias). Diseases of the peripheral nervous 
system may affect the circulation in two ways: the nerves from 
baroreceptors may be affected, interrupting normal homeostatic reflexes 
on the afferent side or post ganglionic efferent sympathetic fibres may be 
involved in the spinal nerves. The severity of the autonomic failure need 
not parallel the degree of motor weakness.  
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PATHOGENESIS OF DAN 
 Autonomic dysfunction that accompanies diabetic neuropathy is 
the one that has extensively evaluated.6,7,8 Several different factors have 
been implicated in this pathogenic process3. Hyperglycemic activation of 
the polyol pathway leading to accumulation of sorbitol and potential 
changes in the NAD:NADH ratio may cause direct neuronal damage 
and/or decreased nerve blood flow. Activation of protein kinase C induces 
vasoconstriction and reduces neuronal blood flow. Increased oxidative 
stress, with increased free radical production, causes vascular 
endothelium damage and reduces nitric oxide bioavailability. Alternately, 
excess nitric oxide production may result in formation of peroxynitrite 
and damage endothelium and neurons, a process referred to as nitrosative 
stress. In a subpopulation of individuals with neuropathy, immune 
mechanisms may also be involved. Reduction in neurotrophic growth 
factors, deficiency of essential fatty acids, and formation of advanced 
glycosylation end products (localized in endoneurial blood vessels) also 
result in reduced endoneurial blood flow and nerve hypoxia with altered 
nerve function. The result of this multifactorial process may be activation 
of polyADP ribosylation depletion of ATP, resulting in cell necrosis and 
activation of genes involved in neuronal damage.  
 Duchen and Coworkers9 attributed the autonomic disorder to 
vacuolization of sympathetic ganglionic nervous, cell nervous and 
inflammation, loss of myelinated fibres in the vagi and white rami 
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communicantes and loss of lateral horn cells in the spinal cord. They 
believe the later changes to be secondary. 
Clinical features of Autonomic Dysfunction can be divided as 
follows10 
(i) Cardiovascular symptoms: Postural hypotension, vertigo, 
syncope, dizziness, blurring of vision, neck pain, weakness.  
(ii) Upper GI symptoms: Dysphagia, nausea, emesis, early satiety, 
bloating. 
(iii) Lower GI symptoms: Nocturnal Diarrhea, constipation 
involuntary loss of stools and incomplete evacuation.  
(iv) Urological symptoms: Dysuria, involuntary dribbling of urine, 
prolonged dribbling, incomplete bladder emptying, Erectile 
dysfunction(ED).  
(v) Others: Hypohydrosis, Gustatory sweating.  
Physiological basis for testing Abnormalities of Autonomic Nervous 
System  
(i) Responses of Blood pressure and Heart Rate to changes in posture 
and breathing. 
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 McLeod and Tuck11 state that in changing from recumbent to 
standing position a fall of more than 30mmHg systolic and 15 mmHg 
diastolic is abnormal; others give figures of 20 and 10mmHg. This 
excessive drop in Blood pressure indicates inadequate sympathetic 
vasoconstrictor activity. In response to the induced drop in blood 
pressure, the pulse rate normally increases. The failure of rise in heart rate 
in response to drop in blood pressure withstanding is a good indication of 
vagal nerve dysfunction12. In addition the pulse after rising initially in 
response to upright posture slows after about 15 beats to reach a stable 
rate by the 30th beat. The ratio of R-R interval in the ECG, corresponding 
to the 30th and the 15th beats is an even more sensitive measure of the 
integrity of Vagal inhibition the sinus node. A ratio in nonelderly of less 
than 1.05 is usually abnormal, indicating loss of vagal tone12. 
 Another simple procedure for quantification of vagal function 
consists of measuring the variation in heart rate during deep breathing. 
Normally heart rate varies by as many as 15 beats per minute or even 
more, between expiration and inspiration; differences of less than 10 
beats per minute may be abnormal12. Measurement of HRV at the time of 
diagnosis of type 2 diabetes serves to establish a baseline, with which 1-
year interval tests can be compared. Regular HRV testing provides early 
detection and thereby promotes timely diagnostic and therapeutic 
interventions. HRV testing may also facilitate differential diagnosis and 
the attribution of the symptoms (e.g., erectile dysfunction, dyspepsia, and 
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dizziness) to autonomic dysfunction. In Valsalva maneuver, the subject 
exhales into a manometer or against a closed glottis for 15 seconds. 
Creating a markedly positive intra- thoracic pressure.  
 The response to performance of the Valsalva maneuver has four 
phases3 and in healthy individuals can be observed as follows:  
• Phase I: Transient rise in blood pressure and a fall in heart rate due 
to compression of the aorta and propulsion of blood into the 
peripheral circulation. Hemodynamic changes are mostly secondary 
to mechanical factors.  
• Phase II: Early fall in blood pressure with a subsequent recovery of 
blood pressure later in the phase. The blood pressure changes are 
accompanied by an increase in heart rate. There is a fall in cardiac 
output due to impaired venous return causing compensatory cardiac 
acceleration, increased muscle sympathetic activity, and peripheral 
resistance.  
• Phase III: Blood pressure falls and heart rate increases with 
cessation of expiration.  
• Phase IV: Blood pressure increases above the baseline value 
(overshoot) because of residual vasoconstriction and restored 
normal venous return and cardiac output. 
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 The response is mediated through alternating activation of 
parasympathetic and sympathetic nerve fibers. Failure of the heart rate to 
rise during positive intra thoracic pressure indicates sympathetic 
dysfunction and failure of the heart rate to slow during blood pressure 
overshoot indicates parasympathetic dysfunction. In patients with 
autonomic failure, the fall in BP is not aborted during the last few 
seconds of increased intra thoracic pressure and there is no over shoot of 
BP when breath is released 12. 
Vasomotor reactions 
 Measurement of the skin temperature is a useful index of 
vasomotor function.  The integrity of sympathetic reflex arc which 
includes baroreceptors of the aorta and carotid sinus, their afferent 
pathways, the vasomotor centers and the sympathetic and 
parasympathetic outflow, can be tested in a general way by the cold 
pressor test, grip test, mental arithmetic test and Valsalva maneuver. 
 Vasoconstriction induces an elevation in Blood pressure. Similarly 
the sustained isometric contraction of a group of muscles for say 5 
minutes normally increases the heart rate and the systolic and diastolic 
pressure by at least 15mmHg 34. The response to both tests is impaired, 
particularly with lesion of the efferent fibers of the sympathetic reflex 
arc12. 
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Sudomotor function 
 Test for integrity of efferent sympathetic pathway. In sympathetic 
or galvanic skin- resistance test, a set of electrodes placed on the skin 
measures the resistance to passage of weak current in skin, the change in 
electric potential is the result of a ionic current within sweat glands. The 
response depends on sympathetic response to sweat glands (Gutrecht)13. 
A more quantitative and reproductive method is examination of 
postganglionic sudomotor function termed QSART (quantitative 
sudomotor axon reflex test)14. The QSART involves iontophoresis of a 
cholinergic agonist to measure axon reflex-medicated sudomotor 
responses quantitatively to evaluate postganglionic sudomotor function. 
Four sites are used and studied simultaneously with the patient supine. 
The test, typically done by recording from the forearm and three lower-
extremity skin sites, has high sensitivity, specificity, and reproducibility, 
with a coefficient of variation of 20% if performed by trained personnel. 
The test is not generally available and requires the purchase of expensive 
specialized equipment. 
Assessing Pupillary function  
 Patients with DAN show delayed or absent reflex response to light 
and diminished hippus due to decreased sympathetic activity and reduced 
resting pupillary diameter15. Pupillary measurements are usually only 
performed in a research setting. 
 20 
 
Cardiac autonomic neuropathy (CAN)         
 CAN probably contribute to the poor prognosis of CHD and CHF 
in diabetes. The majority of patients with CAN come to clinical attention 
with complaints of postural hypotension, resting tachycardia, exercise 
intolerance (or) prior myocardial ischemia (or) infarction. The risk for 
CAN depends on the duration of diabetes and the degree of glycemic 
control and leads to parallel the development of other end organ disease 
related to diabetes such as retinopathy, nephropathy and vasculopathy. 
Symptoms and signs of CAN often occur relatively late in the natural 
history of this complication. 1 
Simple bedside tests for cardiac autonomic neuropathy diagnosis16:  
Heart rate variability test Blood pressure test 
Score Deep 
breathing 
Valsalva 
ratio 
Response to 
standing 
Response to 
handgrip 
Response 
to 
standing 
0 >15 >1.20 >15 >15 ≤ 10 
1 11-15 1.11-1.20 12-15 11-15 11-29 
2 ≤ 10 ≤1.10 <12 ≤ 10 >30 
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 For grading of cardiovascular autonomic function, results are 
classified into normal, borderline and abnormal (scores 0,1,2 
respectively). An overall score of ‘0’ or ‘1’ was considered normal, score 
2,3,4 were considered borderlines and score ≥5 were judged was 
abnormal autonomic function16. 
Prevalence of Cardiac autonomic neuropathy (CAN) 17 
The reported prevalence of CAN varies with the population studied 
and methods used. Regarding of these variations CAN appears to be 
common in diabetes. A summary of 15 reports on CAN suggests that the 
prevalence is in between 2.6 and 90% in diabetic population. The average 
incidence is about 30%. 
Pathology of Autonomic neuropathy in Diabetes9 
 Pathologic changes in the autonomic nervous syndrome were 
studied postmortem in many diabetic cases. All had clinical evidence of 
peripheral sensory motor neuropathy and developed disturbances of 
autonomic function that included postural hypotension, diarrhea, bladder 
dysfunction and signs of cardiac denervation. In celiac and other 
sympathetic ganglia there were many distended (Giant) or vacuolated 
nervous as well as enlarged club shaped neural processes. The vagus 
nerve and sympathetic trunks showed severe loss of myelinated fibers 9. 
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 There were inflammatory changes in autonomic ganglia in all cases 
and in (or) around bundles of unmyelinated nerve fibers in many. These 
findings suggest that there may be several different pathogenetic 
mechanisms involved in the development of autonomic neuropathy in 
diabetes. 9 
Diabetic patients have a high rate of Coronary Artery disease, 
which may be asymptomatic owing to autonomic neuropathy. Silent 
ischemia is significantly more frequent in patients with autonomic 
neuropathy than in those without autonomic neuropathy (38% versus 
5%).18 
It is clear however that a reduced appreciation of ischemic pain can 
impair timely recognition of myocardial ischemia (or) infarction and there 
by delay in initiating appropriate therapy. 18 
In non-diabetic patients, acute myocardial infarction has a circadian 
variation with a significant morning peak. The characteristic diurnal 
variation in the occurrence of myocardial infarction is altered in diabetic 
patients with a lower morning peak and higher percentage of infarction 
during evening hours. The blunted morning surge of incidence of 
myocardial infarction results from altered sympatho-vagal balance in 
patients with cardiac autonomic neuropathy. Mortality rates after a 
myocardial infarction are also higher for diabetic patients than for non-
diabetic patients. This may be due to autonomic insufficiency, increasing 
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the tendency for development of ventricular arrhythmia and 
cardiovascular events after infarction.18 
Autonomic manifestations 
Abnormal autonomic function tests are often found in patients with 
clinical features of sensory neuropathy, and almost any aspect of 
autonomic function can be affected. However, symptoms of autonomic 
neuropathy are not always present and are commonest in patients with 
poorly controlled type I diabetes. In all of the autonomic syndromes 
described below, symptoms may be chronic or strikingly intermittent. 19 
Most longitudinal studies point to a common sequence of 
autonomic involvement in patients with diabetic autonomic neuropathy. 
In the cardiovascular system, the earliest abnormality detected by 
systematic and sensitive testing is a decrease in heart- rate variability 
during deep breathing, followed by alterations in the heart rate on 
standing and then the Valsalva maneuver. Postural hypotension is a 
relatively late event. This progression suggests that parasympathetic 
(vagal) fibers are damaged first, followed by the sympathetic outflow. 
Abnormal autonomic function tests are much more common than 
significant autonomic symptoms. 19 
Symptomatic, but not asymptomatic, autonomic neuropathy has 
been associated with a poor prognosis. But there is dispute as to whether 
 24 
 
this is related to the neuropathy itself or to coexistent macrovascular 
disease or other complications. 19 
Resting Tachycardia 
        Whereas abnormalities in HRV are early findings of CAN, resting 
tachycardia and a fixed heart rate are characteristic late findings in 
diabetic  patients with vagal impairment5. Resting heart rates of 90 to 100 
bpm and occasional heart rate increments up to 130 bpm occur. The 
highest resting heart rates have been found in patients with 
parasympathetic damage, occurring earlier in the course of CAN than 
sympathetic nerve function; in those with evidence for combined vagal 
and sympathetic involvement, the rate returns toward normal but remains 
elevated. A fixed heart rate that is unresponsive to moderate exercise, 
stress, or sleep indicates almost complete cardiac denervation5. Thus, 
heart rate may not provide a reliable diagnostic criterion of CAN in the 
absence of other causes unless it is increased by more than 100 bpm. 
Exercise Intolerance 
 Autonomic dysfunction impairs exercise tolerance20, reduces 
response in heart rate and blood pressure (BP) and blunts increases in 
cardiac output in response to exercise21. Diabetic patients who are likely 
to have CAN should be tested for cardiac stress before undertaking an 
exercise program22. Patients with CAN need to rely on their perceived 
exertion, not heart rate, to avoid hazardous levels of intensity of exercise. 
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Presently, there is inadequate evidence to recommend routine screening 
of asymptomatic diabetic patients with an exercise ECG test. Emerging 
data support the utility of stress imaging testing in identifying diabetic 
patients with preclinical coronary artery disease, particularly patients with 
high-risk features, and comorbidities such as long-standing disease, CAN, 
multiple chronic renal failures, resting ECG abnormalities, and peripheral 
artery disease. 
Abnormal sweating 
This is one of the commonest, but frequently neglected, symptoms 
of diabetic autonomic neuropathy. Gustatory sweating, precipitated by 
eating cheese and other foods, is characteristic. Sweating is often profuse 
over the face and sometimes upper chest, corresponding to the area 
supplied by the superior cervical ganglion. Some patients find this 
socially debilitating. 
 Other abnormalities of sweating include the dry neuropathic foot, 
which allows cracking of the skin and the entry of infection and episodic 
nocturnal sweating that cannot be attributed to hypoglycemia.19 
Cardiovascular changes 
 These include abnormalities of the cardiovascular reflexes related 
to changes in posture and respiration, with severe postural hypotension in 
extreme cases. 19 
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Postural hypotension 
This is due to the impairment of the increase in cardiac output and 
of the sympathetically mediated vasoconstrictor response in the lower 
limbs, which normally follow standing upright. In diabetic neuropathy, 
this is a common manifestation of sympathetic denervation. It can be 
exacerbated by administration of insulin (which acts as a vasodilator at 
pharmacological concentrations) and of diuretics, antihypertensives and 
tricyclic antidepressants (which also have vasodilator activity). On 
standing, blood pressure is normally maintained, may rise slightly or may 
fall, but the systolic drop does not usually exceed 10 mmHg; a significant 
drop is generally taken as > 30 mmHg, although the magnitude of the 
systolic fall on standing does not correlate tightly with symptoms of 
dizziness.19 Postural hypotension is often worse on getting out of bed in 
the morning, but often varies substantially with time. The diagnosis is 
made simply by measuring the blood pressure with the patient lying and 
then standing for up to 2 min (some patients show a delayed fall).19 
Autonomic Cardiopathy5 
 CAN  may be associated with abnormalities in LV systolic and 
particularly diastolic function in the absence of cardiac disease in diabetic 
patients. A review of diabetic cardiopathy other than that ascribed to 
CAN has recently been published23 and is beyond the scope of this 
review. Echocardiographic studies have shown a significant correlation of 
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the severity of CAN with reduced peak diastolic filling rate and with an 
augmented atrial contribution to diastolic filling as assessed by Doppler 
echocardiography. It is difficult to judge, however, whether CAN is an 
independent contributor to these abnormalities, because other factors such 
as interstitial myocardial fibrosis and microangiopathic or metabolic 
changes (discussed in the pathogenesis of diabetic heart muscle disease) 
may also be responsible for LV dysfunction. CAN is associated with LV 
diastolic dysfunction (LVDD) at rest, both in patients with long-term type 
225 or type 1 diabetes24. LVDD may progress to heart failure, mainly with 
preserved LV systolic function (diastolic heart failure), which is also 
related to high morbidity and mortality rates.26,27 The pathophysiology of 
LVDD includes delayed relaxation, impaired LV filling, and/or increased 
stiffness28. Diabetes mellitus can produce functional, biochemical, and 
morphological myocardial abnormalities independent of coronary 
atherosclerosis and hypertension, contributing to heart failure with 
normal LV systolic function29. 
Silent myocardial ischemia/cardiac denervation syndrome 
 The perception of angina was severely impaired in the diabetic 
patients, allowing these individuals to exercise longer after the onset of 
myocardial ischemia. The delay in perception of angina was associated 
with the presence of cardiovascular autonomic dysfunction. The 
investigators suggested that the neuropathic damage to the myocardial 
sensory afferent fibers in the autonomic nerve supply reduced the diabetic 
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individual’s sensitivity to regional ischemia by interrupting pain 
transmission 30. The presence of CAN does not exclude painful 
myocardial infarction (MI) among individuals with diabetes 31. Chest pain 
in any location in a patient with diabetes should be considered to be of 
myocardial origin until proven otherwise; but, of equal importance, 
unexplained fatigue, confusion, tiredness, edema, hemoptysis, nausea and 
vomiting, diaphoresis, arrhythmias, cough, or dyspnea should alert the 
clinician to the possibility of silent MI 32. 
Association of cerebrovascular disease and CAN 
 The frequency of ischemic cerebrovascular events is increased in 
individuals with type 2 diabetes. The impact of autonomic dysfunction on 
the risk of the development of strokes was examined by Toyry et al. 
Abnormalities of parasympathetic and sympathetic autonomic function 
were found to be independent predictors of stroke in this cohort 33. 
Cardiac Radionuclide Imaging 3 
 Radionuclide techniques for cardiac mapping have recently been 
used to directly quantify cardiac sympathetic innervation in various 
diseases, including CAN. The nonmetabolized norepinephrine analogue 
MIBG participates in norepinephrine uptake in postganglionic 
sympathetic neurons. Several studies have demonstrated decreased 
myocardial MIBG uptake in patients with CAN as assessed by autonomic 
reflex tests. There is evidence to suggest that scintigraphic assessment 
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using MIBG and single–photon emission computed tomography is more 
sensitive in detecting CAN than indirect autonomic reflex testing, 
because MIBG uptake is reduced in patients with normal autonomic 
tests3. The MIBG uptake defects are localized predominantly in the LV 
posterior and inferior segments. In advanced CAN, completely absent 
MIBG uptake may be observed. 
Cardiovascular autonomic neuropathy and increased cardiovascular 
morbidity and mortality in diabetes mellitus possible mechanisms17 
1.  Impaired angina recognition, Silent ischemia and infarction. 
2.  Decreased threshold for ischemia 
- Increased resting heart rate and blunted chronotropic response to 
exercise. 
- Impaired coronary vasomotor regulation. 
3.  Prolonged QT interval 
- Increased lethal arrhythmias and sudden death (with or without 
myocardial ischemia) 
4.  Abnormal diastolic and systolic function 
- Contributes to diabetic cardiomyopathy. Increased cardiac mass 
adversely affects the natural history of congestive heart failure 
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5.  Increased peri-operative risk  
- Increased need for hemodynamic support 
- Reduced hypoxia-induced respiratory drive. 
6.  Alteration of normal circadian variation of sympatho-vagal activity 
- Lack of normal nighttime decrease in blood pressure 
- Loss of night time protection against myocardial infarction 
7.  Increased prevalence of other cardiovascular risk factors and other 
Complications  
Increased microvascular complication 
Increased rate of progression of glomerulopathy 
Increased prevalence of hypertension and dyslipidemias17 
PHARMACOLOGIC MANAGEMENT FOR CONTROL 
DIABETES 
Sulfonylureas 
 Sulfonylureas are the preferred therapy for lean patients with type 2 
diabetics and are used in combinations with other agents in obese type 2 
patients. Sulfonylureas bind to a receptor on the beta cells and inhibit the 
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sodium-adenosine triphosphate (Na-ATP) channel and cause an increase 
in intracellular calcium results in insulin exocytosis. 
 Some experts point to a possible risk of increased myocardial 
damage in patients with known CAD who use sulfonylureas at the time of 
an ischemic event. Prevention of protective ischemic preconditioning of 
the heart by inhibition of the potassium (K)-ATP channel is the putative 
mechanism. The UKPDS data do not support this concern. The authors 
agree and use sulfonylureas in appropriate patients with CAD. 3 
Repaglinide 
 This newer insulin secretagogue binds to a different receptor site 
than do the sulfonylureas on the K-ATP channel. The half-life of this 
agent is 3.7h, which makes it effective for postprandial rather than 
preprandial hyperglycemia, for use in the elderly and for diabetic patients 
with chronic renal failure.  
Metformin 
 Metformin is a biguanide drug that has been in use for over 30 
years. The main mode of action of metformin is decreasing hepatic 
glucose output primarily by inhibiting gluconeogenesis, typically without 
hypoglycemia. Metformin is effective alone or in combination with 
insulin, sulfonylureas, and thiazolidinediones. The drug usually results in 
weight loss as a result of decreased appetite for up to 1 year after the 
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inititation of therapy.  Significant decrease in LDL cholesterol and 
triglycerides occur. The incidence of lactic acidosis with metformin is 9 
per 100,000 person-years. Contraindications to its use include an elevated 
creatinine level (>1.4 in women, >1.5 in men), congestive heart failure, 
severe pulmonary disease, or any hypoxic state.  
Thiazolidinediones 
 Thiazolidinediones promote insulin-stimulated glucose transport in 
muscles and adipocytes through a mechanism of action involving  
peroxisome proliferators activated receptor-gamma (PPAR-γ) ligands. 
Binding to the nuclear receptor promotes differentiation of adipocytes 
and increased expression of glucose transporter. Thiazolidinediones has 
been shown to be effective both as monotherapy and in combination with 
insulin, sulfonylureas, and metformin.  
Rosiglitazone monotherapy results in a decrease of Hb A1c of 0.8 
to 1.5 percent greater than that seen with placebo, with the greatest 
reduction seen when it was given in two divided doses. Combination 
studies of rosiglitazone with metformin for 26 weeks resulted in a 1.0 to 
1.2 percent placebo-adjusted decrease in HbA1c. Although rosiglitazone 
is currently approved for use as monotherapy and in combination therapy 
with metformin, it also is expected to be efficacious with sulfonylureas or 
insulin. Rosiglitazone has been reported to result in an increase in LDL 
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and HDL cholesterol concentrations between 12 and 19 percent, with 
changes in serum triglycerides similar to those seen with placebo.  
 Pioglitazone, the newest thiazolidinedione, has been approved for 
use as monotherapy and in combination with metformin, sulfonylureas, 
and insulin. Weight gain(20%), ankle edema and fluid overload are the 
common side effects. Hepatotoxicity can occur. Contraindicated in 
Volume overload states, Hepatitis, Ischemic heart disease and macular 
edema.   
Alpha-Glucosidase Inhibitors 
Acarbose and miglitol work in the intestine to reversibly inhibit 
brush border alpha-glucosidases, resulting in a delay in carbohydrate 
absorption. These agents are poorly  absorbed from the gastrointestinal 
tract. These drugs cause a 30 percent decrease in postprandial glucose in 
contrast to a 10 percent decrease in fasting glucose levels. They are 
adjuncts to other oral agents and rarely are potent enough to be used as 
mono therapy.  
GLP Analogues and Di peptidylpeptidase inhibitors1 
 Incretin hormones potentiate glucose mediated insulin response 
and is chiefly caused by two peptide hormones – Glucose dependent 
insulin releasing polypeptide(GIP) and glucagon-like peptide(GLP-1). 
GLP-1 is mainly produced by the enteroendocrine L cells located in the 
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distal intestine. GIP and GLP-1 is rapidly inactivated by the enzyme 
dipeptidyl peptidase-IV (DPP – IV). Newer therapeutic candidates for the 
treatment of type 2 diabetes are those drugs that enhance glucose 
dependent insulin secretion called Incretin mimetics. The use of DPP-IV 
inhibitors to improve the duration of endogenous GLP-1 ativity to target 
post-prandial glucose excursions along with effects on fasting glucose 
levels. They do not demonstrate any hypoglycemic effects. Sitagliptin is 
the first approved drug which can be used as monotherapy or 
combination therapy. Reduced hypoglycemic effect and reduced weight 
gain are the advantages over Sulphonylureas.  
Insulin 
 The natural history of type 2 diabetes is one of progressive beta-
cell failure. Therefore, after approximately 10 years of the use of oral 
hypoglycemic agents, insulin may be required in combination with oral 
agents as the sole therapy. Although endogenous hyperinsulinemia is 
clearly associated with atherogenesis, there is no compelling evidence of 
increased risk of cardiovascular disease or increased mortality from 
exogenous insulin therapy.  
Treatment for Autonomic Dysfunction3 
 Identifying individuals at risk is only the first step in managing 
patients and ultimately affecting outcomes. After identification, effective 
management must be provided. Proactive measures are required, because 
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if those patients at high risk or those shown to be in early stages are not 
treated until advanced symptomatology is present, little has been 
achieved.  
 Unfortunately, information presented at the fifth Regenstrief 
conference on the intensive management of type 2 diabetes indicated that 
physicians may feel that screening is not of value because treatment 
options for identified complications are limited34. Such a view does not 
take into account the clinical research advances that have been made in 
the treatment of diabetes. Tests that provide evidence of further health 
consequences may bring patients to medical attention before other signs 
of diabetic end-organ injury emerge, making proactive treatment, 
particularly the establishment of intensive diabetes care, possible. The 
results of autonomic function testing can contribute to good patient 
management in the following ways.  
To assist in the establishment (or reestablishment) of tight glycemic 
control 
 Early observations by researchers that near-normal glycemic 
control seems to be the most effective way to delay the onset of CAN in 
type 1 diabetes has been confirmed by evidence from the DCCT 35. 
Intensive insulin therapy has been shown to be effective at preventing 
multiple complications in patients with type 1 diabetes and is postulated 
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to be effective for patients with type 2 diabetes, although clinical studies 
are underway in the latter.  
 In its earliest stages, there has been some clinical demonstration 
that autonomic dysfunction may be influenced within a few days to a few 
weeks with effective treatment36,37. Delay in instituting appropriate 
interventions can only increase the likelihood of developing advanced 
neuropathies. Stabilization of the neuropathies (generally considered to be 
any delays in further progression) through tight glycemic control seems 
possible, whereas reversal of the condition may be less likely36. Again, 
the results from the DCCT show that intensive glycemic treatment can 
prevent the development of abnormal heart rate variation and slow the 
deterioration of autonomic dysfunction over time 38.  
 Although the relationship between features of autonomic 
neuropathy and hypoglycemic unawareness is complex and there is 
overlap, it is recognized that autonomic neuropathy may cause or 
contribute to the development of hypoglycemic unawareness. In most 
individuals with hypoglycemic unawareness, raising the target may be 
necessary to prevent repeat episodes. Thus, emphasizing tight control for 
individuals with autonomic dysfunction should also include increased 
vigilance in glycemic monitoring and reeducation of the patient with 
regard to hypoglycemia.  
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To facilitate the decision to initiate treatment for cardiovascular 
autonomic dysfunction3 
 Several different factors have been implicated in the potential 
metabolic-vascular pathogenic process of diabetic neuropathy (e.g., 
activation of the polyol pathway, increased oxidative stress, reduction in 
neurotrophic growth factors, deficiency of essential fatty acids, and 
formation of advanced glycosylation end products). Thus, timely 
identification of autonomic dysfunction in diabetic patients may expedite 
end-organ prophylaxis such as the use of ACE inhibitors and Aspirin and 
the use of pharmacological and non-pharmacological interventions to 
improve blood pressure and lipid control. Improved nutrition and reduced 
alcohol and tobacco consumption are additional options available to 
patients with diabetes who are identified with autonomic nerve 
dysfunction. Interventions to modulate reduced heart rate variation 
currently being studied in clinical trials are based on theories of the 
pathogenesis of CAN.  
 Evidence from clinical trials evaluating the use of antioxidants is 
promising. Early identification of CAN permits timely initiation of 
therapy with the antioxidant Alpha-lipoic acid (thioctic acid), which 
appears to slow or reverse progression of neuropathies in some studies. 
Other antioxidants such as vitamin E have been shown to improve the 
ratio of cardiac sympathetic to parasympathetic tone in type 2 diabetic 
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individuals with CAN  but may mitigate the effects of statins and niacin 
in treating or preventing macrovascular disease.  
 Studies using ACE inhibitors as a means to improve heart rate 
variation have resulted in conflicting results. Whereas quinapril 
significantly increased parasympathetic activity after 3 months of 
treatment, cardiovascular  autonomic function did not change 
significantly after 12 months of treatment with trandolapril. 
 Non-pharmacological measures like adequate intake of salt and 
fluids, in the range of 10 to 20g, of salt / day and 2-3 litres of fluid / day. 
Sleeping with the head end elevated will minimize the effects of supine 
nocturnal hypertension. Patients are advised to sit with legs dangling over 
the edge of the bed for several minutes before attempting to stand. Other 
maneuvers like leg–crossing, contraction of leg muscles for 30 seconds. 
Such measures compress leg vein and increase systemic resistance. 
Compression stocking may be helpful. Anemia should be corrected. 
 Fludrocortisone at dose 0.1 mg/day and 0.3 mg bid orally will 
effectively reduce OH, but aggravate supine hypertension. Potassium 
supplements are necessary with chronic administration of fludrocortisone. 
Postprandial OH can be reduced by frequent small meals. Prostaglandin 
inhibitors taken with meals or midodrine can be used. Somatostatin 
analogue octreotide in dose of 25 µg bid to 100-200 µg tid acts by 
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inhibiting gastrointestinal peptides prevent the vasodilation and 
hypotension effects.  
 The use of cardioselective (e.g., atenolol) or lipophilic (e.g., 
propranolol) ß-blockers may also modulate the effects of autonomic 
dysfunction.32 By opposing the sympathetic stimulus, they may restore the 
parasympathetic-sympathetic balance. Recently, the administration of 
metoprolol to ramipril-treated  diabetic patients with abnormal 
albuminuria has been shown to improve autonomic dysfunction40.  
 Because the pathogenesis of CAN is most likely a multifactorial 
process, a combination of therapies directed simultaneously at different 
parts of the pathogenic pathway may be needed. In addition, the goal of 
these interventions should be directed at the prevention of further 
deterioration of cardiovascular autonomic dysfunction rather than 
expecting to realize improved function.  
To emphasize the importance of adherence to diet and exercise 
interventions 
 It is again emphasized that lifestyle interventions (e.g., adherence 
to diet and exercise) can reduce the incidence of type 2 diabetes. 
Recently, a report indicated that impaired glucose tolerance may be 
associated with the development of diabetic neuropathy (i.e., sensory 
polyneuropathy)41.  This would put even greater emphasis on the 
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importance of lifestyle interventions and screening at or soon after 
diagnosis.  
        Motivation to adhere and remain compliant with non-
pharmacological interventions is difficult. Current research suggests that 
preventive measures (glycemic control, diet, and exercise) introduced to 
the general diabetic population are difficult to sustain and consequently 
less than effective. This is due, in part, to the long-term commitment that 
must be made to the practice of preventive measures. Although 
individuals with diabetes are faced with the immediate pressures of 
disease management on a day-to-day basis, it is the long-term risks of 
micro- and macrovascular complications that pose the most serious 
risks42. The ability to determine early stages of autonomic dysfunction 
could intensify the salience of measures such as diet and exercise that 
directly affect efforts to establish tight glycemic control and delay the 
development of autonomic dysfunction. Colloquial patient management 
strategies could be introduced to a now potentially motivated patient.  
         As mentioned previously, clinicians must be careful when giving 
recommendations with regard to exercise for individuals with CAN. This 
does not mean, however, that exercise is inappropriate for individuals 
with CAN. In fact, Howorka et al.43 showed that physical training 
improved heart rate variation in insulin-requiring diabetic individuals 
with early CAN. Thus, careful testing to evaluate cardiovascular 
autonomic function and its degree of development is extremely important. 
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Clinicians working together with the patient can develop an appropriate 
exercise program that will yield a plan for reaping maximum benefits.    
QTc – Interval and prolongation 
 QT interval taken from the onset of QRS complex to end of the ‘T’ 
wave and corrected for heart rate give the corrected QT interval (QTc). A 
QTc interval of more than 440 millisecond is considered prolonged 44. It 
reflects the total duration of ventricular myocardial depolarization and 
repolarization in the ECG. It is usually corrected for heart rate by Bazett 
formula, where QTc = QT √RR interval. The Bazett formula gives a 
slight over correction of QT interval at higher heart rates. 
Hodges et al57 also gave a formula to get corrected QT as follows: 
QTc = QT + 1.75 (rate-60) and is gaining more acceptance. QTc 
prolongation in ischemic heart disease carries an increased risk (2-5 
times) of sudden cardiac death. 
 The exact mechanism of QTc prolongation is not clearly defined. It 
is generally agreed that parasympathetics have little influence on QTc 
Modulation45. Recently, it has been suggested that some non-quantifiable 
sympathetic imbalance is responsible for QTc prolongation46. A 
prolonged corrected QT interval and QT dispersion (the difference 
between the longest and shortest QT interval) indicates an imbalance 
between right and left sympathetic innervation. QTc interval in the 
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ECG can be used to diagnose CAN with reasonable sensitivity, 
specificity and positive predictive value. 
 QT interval prolongation is an irregularity of the electrical activity 
of the heart that places patients at risk for ventricular arrhythmias39. 
Patients with QT- prolongation are at high risk of serious ventricular 
arrhythmias usually, TdP, although monomorphic ventricular tachycardia 
may also develop41.Alterations in cardiac sympathetic innervation may 
result in QTc prolongation and predispose to arrythmias and sudden 
death. 
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MATERIALS AND METHODS 
STUDY POPULATION       
 A total of 150 patients satisfying all the inclusion and exclusion 
criteria were enrolled for the study from the population of  Type 2 
Diabetes patients who attended the out patient clinics and Inpatients  of 
Institute of Internal Medicine, Government General Hospital . Written 
consent was obtained from all the patients participating in the study after 
clearly explaining the study procedure. 
 The patients were grouped into three according to the duration of 
diabetes. Autonomic neuropathy testing by simple bet side tests was done 
in op department and Medical ward using ECG monitor, Pulseoxymeter 
and BP apparatus for the same 150 patients. Each groups were compared 
with one another with the available statistical data. 
STUDY DURATION 
 This study was conducted for a period from May 2007 to August 
2008. 
STUDY DESIGN 
 A Cross-sectional study to evaluate the Prevalence of 
Cardiovascular Autonomic Neuropathy in Type 2 diabetes and correlate it 
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with duration of Diabetes. To investigate  the relationship between 
cardiac autonomic dysfunction and corrected QT interval.  
METHODS 
 Detailed clinical history was taken from each patients and a 
completes review of their case notes performed. A complete clinical 
examination of the cardiovascular system was done for each patient.  
Tests for autonomic functions   
         On the day of testing patients were instructed not to ingest caffeine 
containing products. All recordings the done 5-8 hours post prandially. 
Blood pressure was recorded manually using standard 
sphygmomanometer. The heart rate variation was calculation using 
standard Heart rate monitor, Pulseoxymeter  and continous ECG 
recording. A baseline ECG was taken with a Standard ECG machine for 
calculation of QTc interval. 
 The simple bedside tests for assessing the autonomic nervous 
system were described by Ewing and Clarke47. All patients were 
subjected to a battery of five tests as described below: 
Heart rate response to valsalva maneuver  
 The subject was seated quietly and then asked to blow into the 
empty barrel of a 20ml syringe attached to a mercury 
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sphygmomanometer, to maintain a pressure of 40 mm Hg for 10 seconds 
The ratio of the maximum heart rate during blowing to the minimum 
during the compensatory bradycardia after stopping is calculated. The 
maneuver was repeated three times with one minute interval in between 
and results were expressed as  
 Valsalva ratio = Max heart rate  ÷ Minimum heart rate.  
 The mean of the three-valsalva ratios was taken as the final value.  
Heart rate variation during deep breathing 
 The subject was asked to breathe deeply at six breaths / min (Five 
seconds “in” and five seconds “out”) for one minute. The average heart 
rate difference (maximum minus minimum during the respiratory cycle) 
is calculated while the patient breaths deeply for 1 min. The results were 
expressed as the mean of the difference between maximum and minimum 
heart rates for the six measured cycles in beats / min.  
Immediate heart rate response to standing  
 The test was performed with the subject lying quietly on a couch. 
The heart rate increase is recorded 15 seconds after standing from lying 
position. Alternatively, the ratio of the R-R interval of the 30th beat after 
standing to that of the 15th beat (’30:15’) can be calculated. 
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Blood pressure response to standing 
 This test measured the subject’s blood pressure with a 
sphygmomanometer while he was lying quietly. Then he was made to 
stand up and the blood pressure again after one minute. The postural fall 
in blood pressure was taken as the difference between the systolic 
pressure lying and the systolic pressure standing. The test was in repeated 
three times and the mean systolic blood pressure was calculated.  
Blood pressure response to sustained hand grip  
 The blood pressure of the patient was taken three times before the 
maneuver. A modified sphygmomanometer was used to sustain handgrip. 
The patient was asked to grip the inflatable rubber and apply maximum 
voluntary pressure possible. A reading from the attached mercury 
manometer was taken during maximum voluntary contraction. There 
after, the patient was asked to maintain 30% of maximum voluntary 
contraction for as long as possible up to five minutes. Blood pressure was 
measured at one minute intervals during the handgrip. The result was 
expressed as the difference between the highest diastolic blood pressure 
during the handgrip exercise and the mean of the three diastolic blood 
pressure readings before the handgrip began.  
 Apart from the tests cardiac autonomic imbalance was also tested 
by detailed history. In the history symptoms suggestive of orthostatic 
intolerance like  
 47 
 
H/o light headedness   
          H/o weakness or tiredness 
         H/o vertigo  
          H/o anxiety  
          H/o palpitations 
          H/o sweating abnormality 
          H/o diarrhea 
          H/o constipation 
 Since cardiac autonomic neuropathy is usually associated with 
other features of autonomic neuropathy this questionnaire was useful in 
assessing the patients along with the bed side tests. 
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INTERPRETATION OF THE TEST WAS BASED ON THE 
WORKS OF EWING AND CLARKE16. 
Heart rate variability test Blood pressure test 
Score Deep 
breathing 
Valsalva 
ratio 
Response to 
standing 
Response to 
handgrip 
Response 
to 
standing 
0 >15 >1.20 >15 >15 ≤ 10 
1 11-15 1.11-1.20 12-15 11-15 11-29 
2 ≤ 10 ≤1.10 <12 ≤ 10 >30 
 
 For grading of cardiovascular autonomic function, results are 
classified into normal, borderline and abnormal (scores 0,1,2 
respectively). An overall score of ‘0’ or ‘1’ was considered normal, score 
2,3,4 were considered borderlines and score ≥5 were judged was 
abnormal autonomic function56. 
 QT interval was taken from the onset of QRS complex to the end 
of T wave. QT was then corrected for heart rate using the Bazette’s 
formule44. 
 QTc interval = QT / √(R – R). A QTc interval more than 440 
Millisecond is considered prolonged.   
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INCLUSION CRITERIA                                       
1) Type 2 diabetes already on treatment and newly diagnosed patients. 
EXCLUSION CRITERIA      
1) Age above 60 years 
2) Documented ischaemic heart disease 
3) Documented valvular or congenital heart disease 
4) Hypertension 
5) COPD 
6) Uraemia 
7) Parkinsonism                         
STATISTICAL ANALYSIS 
 Statistical analysis was carried out for 150 patients after 
categorizing each variable – Age, sex, duration of diabetes, autonomic 
function tests, autonomic dysfunction score, interpretation results and 
QTc interval were analyzed. One way Analysis of variance (ANOVA) 
was performed for comparison of means of more than two groups. The 
significance of difference between the proportions was indicated by the 
chi-square (x2) statistic. The significance of difference in mean between 
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the groups was calculated by student t-test. Variables were considered to 
be significant if (P<0.05). Intervariate analysis was done by using 
Pearson’s r- value correlation.  
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OBSERVATION AND RESULTS 
 
POPULATION CHARACTERISTICS 
 The study group consists of 150 patients with Type 2 diabetes. The 
following  tables lists the information about the age variation and sex 
distribution of the study group. The patients in the groups  <5yrs, 5-10 yrs 
and >10 yrs were taken as group A, B and C respectively.                                        
 
TABLE – 1     AGE VARIATION AMONG STUDY GROUPS 
Duration of DM N Mean age SD 
<5 years 50 50.08 4.251 
5-10 years 50 52.76 3.217 
>10 years 50 55.16 2.881 
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TABLE – 2   SEX DISTRIBUTION AMONG STUDY GROUPS 
 
<5 years 5-10 years >10 years 
Duration of DM 
n % n % n % 
Male 27 54 29 58 28 56  
SEX Female 23 46 21 42 22 44 
Total 50 100 50 100 50 100 
 
 Among 150 patients, 84 patients were men accounting for 56% of 
total patients. The remaining 66(44%) patients were women. Mean age of 
patients  in the groups A, B and C  were 50.8, 52.76 and 55.16 
respectively. This shows there is no significant variation in age among the 
three groups. 
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CARDIOVASCULAR AUTONOMIC DYSFUNCTION IN THE 
STUDY GROUP 
TABLE -3    FREQUENCY DISTRIBUTION OF NORMAL (0-1), 
BORDERLINE (2-4), ABNORMAL (≥5) 
Group 
<5YRS 5-10YRS >10YRS 
CAN 
 
n % n % n % 
Significance 
0-1 36 72 24 48 13 26 
2-4 10 20 14 28 8 16 Score 
≥5 4 8 12 24 29 58 
Total 50 100.0 50 100.0 50 100.0 
P<0.001 
Significant 
 
     In the study population, the prevalence of definite CAN was 8%, 24% 
and 58% in group A, B and C respectively. The prevalence of definite 
CAN increases with increase in duration of diabetes. P value <0.001  
significant. 
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TABLE – 4        MEAN QTc IN THREE STUDY GROUPS 
Duration of DM n Mean SD 
<5YRS 50 416.84 4.251 
5-10YRS 50 426.55 3.217 
>10YRS 50 441.64 2.881 
 
                 TABLE – 5     QTc  RESULT WITH DIAGNOSIS 
Interpretation Screening test 
results Definite CAN+ CAN- 
 
Total 
≤440 9 57 66 
>440 36 16 52 
Total 45 73 118 
 
Sensitivity = 36 / 45 x 100 = 80%  Specificity = 57 / 73 x 100 = 78.08% 
     The QTc values are correlated with the interpretation obtained from 
the Cardiac autonomic function tests. From the table the Sensitivity (i.e) 
the True positives is calculated as 80% and the Specificity (i.e) the True 
negatives is calculated as 78.08% . 
 55 
 
TABLE - 6 
CORRELATION BETWEEN AUTONOMIC NEUROPATHY (AN) 
AND QTc PROLONGATION IN TOTAL DIABETIC PATIENTS 
QTc in 
msec 
Definite 
CAN 
 
% 
Borderline 
CAN 
 
% 
No 
CAN 
 
% 
 
p Value 
≤440 9 20 22 68.8 58 79.5 
>440 36 80 10 31.2 15 20.5 
<0.001 
significant 
 
 
 From the table, QTc interval prolongation occurs with development 
of  CAN. Prolongation of QTc  interval  is well correlated with Cardiac 
Autonomic Neuropathy. P value <0.001. 
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DISTRIBUTION OF SYMPTOMS OF CAN  
AMONG CAN+ve PATIENTS 
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DURATION OF DIABETES AND PREVALENCE OF DEFINITE 
CARDIOVASCULAR AUTONOMIC NEUROPATHY 
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DISCUSSION 
 The results of this study on native Indian population illustrate the 
fact that cardiac autonomic dysfunction is common in Diabetic patients 
and its prevalence increases with duration of diabetes. Similar results 
have been reported in previous studies conducted in India and other 
countries48-51. This study demonstrated significant abnormalities in 
autonomic function using basic cardiovascular autonomic function tests, 
which have well been validated. 
 Vinik et al 3 studied and published a data of sensitivity of 
Autonomic function tests done on a population of 3516 patient with type 
1 and type 2 Diabetes. The calculated sensitivity of HRV during deep 
breath testing and valsalva was 98% and 93% respectively. In our study, 
Heart rate variability during deep breathing is abnormal in 44 out of 45 
patients with definite CAN giving a sensitivity of 97.7%  and valsalva is 
abnormal in 42 of 45 patients with CAN giving a sensitivity of 93% 
which correlates with given values. Abnormal HRV in one test is 
indicative of early autonomic neuropathy3. Meta-analyses of published 
data demonstrate that reduced cardiovascular autonomic function as 
measured by heart rate variability (HRV) is strongly (i.e., relative risk is 
doubled) associated with an increased risk of silent myocardial ischemia 
and mortality3. 
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 Mohan et al51 studied the prevalence of CAN in 336 patients with 
NIDDM in south India. There was an increase in prevalence of CAN with 
duration of diabetes. In 0-5 years group the prevalence of autonomic 
dysfunction was 28.2%. In our study, the prevalence of autonomic 
dysfunctin in 0-5yrs group is 28% of which 8% had definite CAN and 
20% had evidence of  borderline/early CAN. 
 Toyry J P  et al48 studied the clinical significance of autonomic 
neuropathy in NIDDM. A total of 133 patients with newly diagnosed 
NIDDM (70 men) and 144 control subjects (62 men) were examined at 
baseline and after 5 and 10 years of follow-up. The frequency of 
autonomic dysfunction at baseline, at 5 yrs and 10yrs was 4.9%, 19.6% 
and 65% respectively. In our study, the prevalence of definite CAN at 
<5yrs, 5-10yrs and >10yrs is 8%, 24% and 58% respectively which is 
comparable to the above study. Also, the prevalence of cardiovascular 
autonomic neuropathy increases with increase in duration of diabetes 
(p<0.001). 
 Pappachan J M et al52 studied the prevalence the CAN among 100 
type 1 and type 2 diabetes mellitus, in south India assessed by the five 
autonomic function tests by Eving’s methodology. The prevalence of 
CAN was 60%  which is comparable to the results obtained in this study. 
 Vinik et al5 found that parasympathetic damage occurs earlier than 
sympathetic damage in diabetic cardiovascular autonomic neuropathy. 
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Hence the autonomic tests that assess the parasympathetic system which 
include Heart Rate Variability(HRV) to deep breath, valsalva, lying to 
standing becomes abnormal before the blood pressure tests. In our study, 
the patients with borderline CAN almost everyone have abnormalities in 
Heart Rate Variability(HRV) with only few have blood pressure 
abnormalities. This again emphasis the importance of Heart Rate 
Variability testing as screening for early autonomic dysfunction in 
diabetes. 
 The symptoms of Autonomic dysfunction was present only in 19 
out of 45(42.22%) patients with definite CAN. Almost 58% of patients 
with definite CAN were asymptomatic. This clearly shows the 
importance of screening for autonomic dysfunction even in asymptomatic 
diabetics. Patients with severe cardiac autonomic dysfunction have high 
risk of developing silent myocardial infarction and sudden death53. 
 Also, in our study, 14 out of 73(19.1%) patients without CAN had 
symptoms suggestive of autonomic dysfunction. Clinical symptoms of 
autonomic neuropathy generally do not occur until long after the onset of 
diabetes. Whereas symptoms suggestive of autonomic dysfunction may 
be common they may frequently be due to other causes rather than to true 
a autonomic neuropathy3. 
    Chen H S et al4 determined the 8-year survival rate for patients with 
abnormal CVR tests which was 63.6% in males and 76.4% in females, 
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compared with 80.9 and 93.3% for patients with normal CVR test. He 
concluded that Type 2 diabetic patients with abnormal CVR tests may 
have increased mortality, and those combined with postural hypotension 
have higher mortality than those without. Abnormal CVR tests may be 
important predictors of mortality in Type 2 diabetes mellitus. Subclinical 
autonomic dysfunction can, however, occur within a year of diagnosis in 
type 2 diabetes patients and within two years in type 1diabetes patients.3  
Massin et al54 demonstrated that early puberty is a critical period for the 
development of CAN and suggested that all type 1 diabetic patients 
should be screened for CAN beginning at the first stage of puberty. 
 Vinik et al3 proposed the measurement of HRV at the time of 
diagnosis of type 2 diabetes and within 5 years after diagnosis of type 1 
diabetes (unless an individual has symptoms suggestive of autonomic 
dysfunction earlier) serves to establish a baseline, with which 1-year 
interval tests can be compared. Regular HRV testing provides early 
detection and thereby promotes timely diagnostic and therapeutic 
interventions. The  knowledge of early autonomic dysfunction can 
encourage patient and physician to improve metabolic control and to use 
therapies such as ACE inhibitors and ß-blockers, proven to be effective 
for patients with CAN. 
 There were patients with borderline or early autonomic 
dysfunction. Out of  150 patients studied total of 32(21.33%) patients had 
borderline dysfunction, of which 10(20%), 14(28%) and 16(32%) were 
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present in groups representing <5yrs, 5-10yrs and >10yrs duration 
respectively. Identifying these individuals at risk is only the first step in 
managing patients and ultimately affecting outcomes. After identification, 
effective management must be provided. Proactive measures are required, 
because if those patients at high risk or those shown to be in early stages 
are not treated until advanced symptomatology is present, little has been 
achieved. Early observations by researchers that near-normal glycemic 
control seems to be the most effective way to delay the onset of CAN and 
arrest its progression. Hence it is important in emphasizing tight glycemic 
control for individuals with autonomic dysfunction with reeducation of 
the patient with regard to need for regular monitoring and hypoglycemia. 
Thus, timely identification of autonomic dysfunction in diabetic patients 
may expedite end-organ prophylaxis such as the use of ACE inhibitors 
and aspirin and the use of pharmacological and non-pharmacological 
interventions to improve blood pressure and lipid control. Improved 
nutrition and reduced alcohol and tobacco consumption are additional 
options available to patients with diabetes who are identified with 
autonomic nerve dysfunction.3 Early identification of CAN permits timely 
initiation of therapy with the antioxidant alpha-lipoic acid (thioctic acid) 
and Vitamin E, which appears to slow or reverse progression of 
neuropathies in some studies.55  
 In the ECG, out of 45 patients with definite CAN, corrected QT 
interval (QTc) is prolonged in 36(80%) patients, which gives a sensitivity 
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and specificity of 80% and 78.08%. respectively. There was significant 
correlation (p<0.001) between CAN and QTc prolongation in this study 
group. 
 Pappachan J M et al52 studied the utility of prolongation of 
corrected QT interval (QTc) in the ECG to diagnose CAN in patients with 
diabetes. They calculated the sensitivity and specificity of QTc 
prolongation for the diagnosis of CAN were 77% and 62.5% in type 1 
and 76.5% and 75% in type 2, respectively. They concluded that QTc 
interval in ECG can be used to diagnose CAN with reasonable sensitivity 
and specificity. This value of sensitivity and specificity correlates with 
our study. 
 C P Mathur et al56 studied 50 patients with diabetes with 20 normal 
controls to understand the relationship to CAN with QTc interval. There 
were 15 (78.94%) cases with QTc prolongation out of 19 diabetics with 
CAN. None of the diabetics without CAN or control subjects had QTc 
prolongation.It was observed to have sensitivity o9f 82.6% and 
specificity of 100%. This value of sensitivity matches the with our study 
but it does not correlates with specificity value. 
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There were certain limitations in this study:  
 Newer techniques for measuring autonomic functions like the 
computer aided power spectral analysis of heart-rate variability could not 
be done because of limitations in resources and cost. There was no 
facility for measuring Serum Magnesium and Calcium which may alter 
QT interval. No Holter monitoring facility was available to assess the risk 
of ventricular tachycardia in patients with QTc prolongation. It was not 
possible to rule out the possibility of congenital long QT syndrome. 
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CONCLUSION 
 The following are the conclusions from this study: 
1. The Prevalence of Cardiovascular Autonomic Neuropathy is high 
in type 2 diabetics in our hospital. 
2. The prevalence of CAN will increase with increase in the duration 
of diabetes. About half of the patients with type 2 diabetes have 
autonomic dysfunction after ten years. 
3. A significant correlation is present between Cardiovascular 
autonomic dysfunction and QTc prolongation. QTc interval in the 
ECG can be used to diagnose Cardiovascular autonomic 
neuropathy with a reasonable sensitivity and specificity. 
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PROFORMA 
• Name :   • Age     • Sex 
• Smoking / Alcohol Status: 
• Duration of Diabetes: 
• History Suggestive of Autonomic Neuropathy :  
• Examination:     
 Vital Signs: HR:  BP:     
• Examination of cardio vascular system: 
 
[ 
TESTS FOR CARDIO VASCULAR AUTONOMIC FUNCTION 
 
 Test 1 Test 2 Test 3 Mean 
I  Valsalva Ratio     
ii  Deep Breathing Test     
iii       Supine to standing     
iv  BP Response to 
 standing  
    
v  BP Response to 
 sustained Hand grip 
    
 
 
•  Examination of RS,GIT &CNS:  
 
•  ECG:   QTc 
•  Blood Sugar:    
    Urea  
    Creatinine 
